ES2253370T3 - Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica. - Google Patents
Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica.Info
- Publication number
- ES2253370T3 ES2253370T3 ES01926590T ES01926590T ES2253370T3 ES 2253370 T3 ES2253370 T3 ES 2253370T3 ES 01926590 T ES01926590 T ES 01926590T ES 01926590 T ES01926590 T ES 01926590T ES 2253370 T3 ES2253370 T3 ES 2253370T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- chronic fatigue
- cabergoline
- fatigue syndrome
- cabergolina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title claims abstract description 17
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title abstract description 13
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title abstract description 11
- 229960004596 cabergoline Drugs 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 12
- 206010016256 fatigue Diseases 0.000 claims description 8
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000002483 medication Methods 0.000 description 7
- 230000036407 pain Effects 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940052740 other dopaminergic agent in atc Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de cabergolina o una sal farmacéutica- mialgia. mente aceptable de la misma para la fabricación de un medicamento para el tratamiento de síntomas del síndrome de fatiga crónica o del síndrome de fibromialgia.
Description
Cabergolina para el tratamiento del síndrome de
fibromialgia y de fatiga crónica.
La presente invención se refiere al uso de
cabergolina para la preparación de un medicamento para uso en el
tratamiento de síntomas del síndrome de fibromialgia y del síndrome
de fatiga crónica.
El síndrome de fatiga crónica (SFC), también
llamado síndrome de trastornos inmunes de fatiga crónica, gripe del
yuppie, fatiga crónica y síndrome de disfunción inmune y fatiga
crónica, es una afección clínica caracterizada por cansancio
profundo o fatiga. Además, los pacientes con SFC generalmente
presentan varios síntomas no específicos, incluyendo debilidad,
dolores musculares y dolores en general, sueño excesivo, malestar,
fiebre, dolor de garganta, dolor en los ganglios linfáticos,
afectación de la memoria y/o de la concentración mental, insomnio y
depresión. No se conoce hasta el momento la causa exacta del SFC, no
hay pruebas específicas para confirmar el diagnóstico de SFC, a
pesar de que se realizan usualmente una variedad de pruebas, con la
finalidad de excluir otras causas posibles de los síntomas.
El síndrome de fibromialgia (SFM), también
llamado fibromialgia, fibromiositis, fibrositis o síndrome de dolor
miofascial, es una afección reumática generalmente caracterizada por
dolor generalizado en tejidos fibrosos, músculos, tendones y otros
tejidos conectivos, fatiga, dolor de cabeza, falta de sueño
reparador y entumecimiento. Por lo tanto, el SFM comparte muchas
características clínicas con el SFC. Al igual que para el SFC, no
hay pruebas diagnósticas para el SFM.
Muchas medicaciones son usadas comúnmente para
tratar el SFC y el SFM. Los ejemplos de medicaciones más comunes
incluyen hipnóticos, inmunosupresores, otras varias medicaciones con
receta médica, y una serie de medicaciones sin receta. Los ejemplos
de tales fármacos recetados incluyen antagonistas opiáceos, agentes
betabloqueantes que retienen sodio, bloqueantes de canales de
calcio/bloqueantes de histamina, antidepresivos, medicaciones para
la alergia y medicaciones para la ansiedad aguda.
No existen medicaciones conocidas que resuelvan
permanentemente los síntomas de SFC o SFM. Además, muchas de las
medicaciones comúnmente usadas producen efectos secundarios que
pueden ir desde leves, por ej. somnolencia, mareos y náuseas, hasta
serios, por ej. adicción y daño hepático.
Cabergolina es el nombre genérico del ingrediente
activo de comprimidos de Dostinex® o Cabaser®, que se comercializan
en los Estados Unidos, Europa y Latinoamérica como tratamiento para
afecciones con hiperprolactinemia y enfermedad de Parkinson. Se
provee un prospecto incluido en el envase de Cabaser®, su
farmacocinética, estudios clínicos, indicaciones y forma de uso,
contraindicaciones y advertencias en pacientes con enfermedad de
Parkinson.
La síntesis y uso de cabergolina se describen en
el documento US-A-4526892. El nombre
químico de la cabergolina es
1-((6-alilergolin-8\beta-il)carbonil)-1-(3-(dimetilamino)propil)-3-etilurea.
De acuerdo con la presente invención, la
cabergolina o una sal farmacéuticamente aceptable de la misma se usa
para la fabricación de un medicamento para el tratamiento de los
síntomas de SFC o SFM.
Se pueden usar preparaciones farmacéuticas
convencionales para cabergolina, por ej. compuestas esencialmente
por un vehículo farmacéutico inerte y una dosis eficaz de la
sustancia activa, por ej. comprimidos recubiertos o no recubiertos,
cápsulas, pastillas, polvos, soluciones, suspensiones, emulsiones,
jarabes o supositorios. Una forma farmacéutica de preferencia es el
comprimido.
El intervalo de dosificación eficaz para
cabergolina es 0,01 a 10,0, de preferencia 0,25 a 10,0, de más
preferencia 1 a 6, y aún de mayor preferencia 1 a 2,
mg/dosis/paciente por vía oral. En estos niveles o en niveles
mayores de dosificación, la cabergolina se administra típicamente
una vez o dos veces al día; sin embargo, para algunos pacientes la
frecuencia de dosificación puede reducirse a tres, dos o aún una vez
a la semana. El médico tratante puede ajustar fácilmente la
combinación de niveles de dosificación y frecuencia de dosificación
para un paciente en par-
ticular.
ticular.
La respuesta a la dosis de cabergolina en
términos de eficacia y efectos secundarios parece estar ligada a la
sensibilidad individual. Bajo ciertas circunstancias y con el
paciente adecuado, puede obtenerse la optimización de la dosis, por
ejemplo, administrando una dosis inicial baja de cabergolina al
paciente hasta una dosis de 0,5 a 1 mg/paciente/día y ajustando la
dosis hacia arriba en intervalos semanales hasta una dosificación
terapéutica óptima de 2, 4, 6, 8 ó 10 mg/paciente/día. Se espera que
los pacientes con formas leves de la enfermedad necesiten menos
fármaco. Por ejemplo, en algunos casos una dosis de 0,5 a 1
mg/paciente/día o aún 0,25 mg/paciente/día puede ser adecuada. Se
espera que los pacientes con formas más severas de la enfermedad y
aquellos que fueron tratados con otros agentes dopaminérgicos
necesiten más fármaco. La dosificación precisa sería determinada
fácilmente por el médico tratante evaluando factores tales como la
progresión del estado de la enfermedad, la edad y peso del paciente,
si se le administraron y en qué cantidad otros fármacos tales como
L-dopa, y otros factores como los que habitualmente
evalúa un médico antes de determinar la dosificación de un fármaco
para el SNC a un paciente.
Claims (1)
1. El uso de cabergolina o una sal
farmacéuticamente aceptable de la misma para la fabricación de un
medicamento para el tratamiento de síntomas del síndrome de fatiga
crónica o del síndrome de fibromialgia.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19895900P | 2000-04-21 | 2000-04-21 | |
| US198959P | 2000-04-21 | ||
| US20056900P | 2000-04-28 | 2000-04-28 | |
| US200569P | 2000-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2253370T3 true ES2253370T3 (es) | 2006-06-01 |
Family
ID=26894316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01926590T Expired - Lifetime ES2253370T3 (es) | 2000-04-21 | 2001-04-17 | Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6448258B2 (es) |
| EP (1) | EP1274430B1 (es) |
| JP (1) | JP2004502650A (es) |
| KR (1) | KR20040007215A (es) |
| CN (3) | CN1450898A (es) |
| AR (3) | AR028355A1 (es) |
| AT (1) | ATE312608T1 (es) |
| AU (2) | AU5311401A (es) |
| BR (1) | BR0110210A (es) |
| CA (1) | CA2405565A1 (es) |
| DE (1) | DE60115872T2 (es) |
| DK (1) | DK1274430T3 (es) |
| ES (1) | ES2253370T3 (es) |
| NZ (3) | NZ531171A (es) |
| PE (1) | PE20011212A1 (es) |
| WO (1) | WO2001081343A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| CN1418099A (zh) * | 2000-04-21 | 2003-05-14 | 法玛西雅厄普约翰美国公司 | 用于治疗肌纤维疼痛和慢性疲劳综合征的精选化合物 |
| AR033520A1 (es) * | 2000-04-27 | 2003-12-26 | Upjohn Co | (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona |
| MXPA03001472A (es) * | 2000-08-16 | 2003-06-06 | Upjohn Co | Compuestos para el tratamiento de trastornos adictivos. |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AR031152A1 (es) | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
| EP1545521A2 (en) * | 2002-10-04 | 2005-06-29 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
| US20040138200A1 (en) * | 2002-10-04 | 2004-07-15 | Michael Hawley | Pharmaceutical compositions for treatment of Parkinson's disease |
| BRPI0613430A2 (pt) | 2005-07-13 | 2011-01-11 | Hoffmann La Roche | compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| ES2332645B1 (es) * | 2009-06-30 | 2010-10-18 | Grifols, S.A. | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
| WO2012039660A1 (en) * | 2010-09-20 | 2012-03-29 | A. Carlsson Research Ab | Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| DE102014008742A1 (de) * | 2014-06-12 | 2015-12-17 | Daimler Ag | Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| US10702512B2 (en) | 2015-05-13 | 2020-07-07 | A. Carlsson Research Ab | Treatment of debilitating fatigue |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| KR0167346B1 (ko) | 1989-06-09 | 1999-01-15 | 로버트 에이. 아미테이지 | 중추신경계 활성을 갖는 헤테로사이클릭 아민 |
| WO1992018475A2 (en) | 1991-04-17 | 1992-10-29 | The Upjohn Company | Substituted phenylazacycloalkanes as cns agents |
| ATE159943T1 (de) | 1993-07-27 | 1997-11-15 | Upjohn Co | Heterozyclische amine mit zns-wirksamkeit |
| JPH1053525A (ja) * | 1996-06-06 | 1998-02-24 | Bitakain Seiyaku Kk | 疼痛治療剤 |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| WO2000054773A1 (en) * | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| DE60022692T2 (de) * | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| AU6917400A (en) | 1999-08-31 | 2001-03-26 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
-
2001
- 2001-04-17 CN CN01806849A patent/CN1450898A/zh active Pending
- 2001-04-17 AU AU5311401A patent/AU5311401A/xx active Pending
- 2001-04-17 EP EP01926590A patent/EP1274430B1/en not_active Expired - Lifetime
- 2001-04-17 NZ NZ531171A patent/NZ531171A/en unknown
- 2001-04-17 CN CNA2004100476387A patent/CN1554343A/zh active Pending
- 2001-04-17 DE DE60115872T patent/DE60115872T2/de not_active Expired - Fee Related
- 2001-04-17 DK DK01926590T patent/DK1274430T3/da active
- 2001-04-17 US US09/836,660 patent/US6448258B2/en not_active Expired - Fee Related
- 2001-04-17 CN CNA2004100476391A patent/CN1554341A/zh active Pending
- 2001-04-17 ES ES01926590T patent/ES2253370T3/es not_active Expired - Lifetime
- 2001-04-17 AT AT01926590T patent/ATE312608T1/de not_active IP Right Cessation
- 2001-04-17 NZ NZ522112A patent/NZ522112A/en unknown
- 2001-04-17 JP JP2001578433A patent/JP2004502650A/ja active Pending
- 2001-04-17 AU AU2001253114A patent/AU2001253114B2/en not_active Ceased
- 2001-04-17 KR KR1020027014072A patent/KR20040007215A/ko not_active Withdrawn
- 2001-04-17 WO PCT/US2001/010807 patent/WO2001081343A2/en not_active Ceased
- 2001-04-17 BR BR0110210-9A patent/BR0110210A/pt not_active IP Right Cessation
- 2001-04-17 CA CA002405565A patent/CA2405565A1/en not_active Abandoned
- 2001-04-17 NZ NZ531172A patent/NZ531172A/en unknown
- 2001-04-19 PE PE2001000357A patent/PE20011212A1/es not_active Application Discontinuation
- 2001-04-20 AR ARP010101861A patent/AR028355A1/es unknown
-
2002
- 2002-05-30 US US10/159,913 patent/US6555548B2/en not_active Expired - Fee Related
-
2003
- 2003-03-07 US US10/383,467 patent/US20030191149A1/en not_active Abandoned
- 2003-04-10 AR ARP030101258A patent/AR039632A2/es unknown
- 2003-04-10 AR ARP030101259A patent/AR039633A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE312608T1 (de) | 2005-12-15 |
| CN1450898A (zh) | 2003-10-22 |
| BR0110210A (pt) | 2003-01-28 |
| US6555548B2 (en) | 2003-04-29 |
| NZ531172A (en) | 2005-07-29 |
| NZ522112A (en) | 2004-10-29 |
| AR028355A1 (es) | 2003-05-07 |
| CN1554341A (zh) | 2004-12-15 |
| EP1274430B1 (en) | 2005-12-14 |
| DE60115872T2 (de) | 2006-07-13 |
| US20030191149A1 (en) | 2003-10-09 |
| WO2001081343A3 (en) | 2002-02-28 |
| DE60115872D1 (de) | 2006-01-19 |
| EP1274430A2 (en) | 2003-01-15 |
| US20020143010A1 (en) | 2002-10-03 |
| DK1274430T3 (da) | 2006-02-13 |
| AU5311401A (en) | 2001-11-07 |
| JP2004502650A (ja) | 2004-01-29 |
| CN1554343A (zh) | 2004-12-15 |
| US6448258B2 (en) | 2002-09-10 |
| WO2001081343A2 (en) | 2001-11-01 |
| KR20040007215A (ko) | 2004-01-24 |
| AU2001253114B2 (en) | 2005-08-25 |
| NZ531171A (en) | 2005-03-24 |
| CA2405565A1 (en) | 2001-11-01 |
| PE20011212A1 (es) | 2001-11-21 |
| AR039632A2 (es) | 2005-03-02 |
| AR039633A2 (es) | 2005-03-02 |
| US20020004510A1 (en) | 2002-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2253370T3 (es) | Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica. | |
| Lindsay et al. | The depression-pain syndrome and its response to antidepressants | |
| Glassman et al. | Potentiation of a monoamine oxidase inhibitor by tryptophan | |
| ES2979034T3 (es) | Procedimientos de tratamiento del síndrome de Lennox-Gastaut mediante el uso de fenfluramina | |
| Giang et al. | Conditioning of cyclophosphamide-induced leukopenia in humans | |
| BR112020002077A2 (pt) | usos combinados de lasmiditan e de um antagonista de cgrp na preparação de medicamentos para tratamento de enxaqueca e outras dores de cabeça | |
| Braga et al. | Comparison of the effects of pilocarpine and cevimeline on salivary flow | |
| JPH0667841B2 (ja) | 恐慌障害の軽減剤 | |
| Tong et al. | Phencyclidine poisoning | |
| ES2468217T3 (es) | Composiciones de fármacos antiinflamatorios no esteroideos descongestivos y antihistam�nicos | |
| Wall III | Use of analgesics in the elderly | |
| AU2002226427B2 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| US6835728B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
| JPS63243028A (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| Simons | Non‐cardiac adverse effects of antihistamines (H1‐receptor antagonists) | |
| ES2231162T3 (es) | 3-ciclopropilmetoxi-4-difluorometoxi-n-(33,5-dicloropirid-4 il)benzamida en el tratamiento de la esclerosis multiple. | |
| Eveloff | Psychopharmacologic Agents in Child Psychiatry: A Survey of the Literature Since 1960 | |
| Inchiosa Jr et al. | Treatment of complex regional pain syndrome type I with oral phenoxybenzamine: rationale and case reports | |
| JP2006527238A (ja) | 過剰体重又は過剰体重に対する素因を有する患者の統合失調症を治療するためのアセナピン | |
| Jaffé et al. | Randomized single-blind trial in general practice comparing the efficacy and palatability of two cough linctus preparations,‘Pholcolix’and ‘Actifed'Compound, in children with acute cough | |
| ES2292794T3 (es) | Compuestos para la supresion y/o alivio de la anhedonia. | |
| TW448044B (en) | Pharmaceutical composition of selegiline for the treatment of epileptic disorders | |
| Brampton et al. | Double-blind crossover study of the efficacy and acceptability of oxazepam Expidet® tablets compared to placebo in patients undergoing gynaecological surgery | |
| WO2018109935A1 (ja) | Ｐｔｓｄ患者において悪夢を予防、改善、又は治療する薬剤 | |
| Moon | ABHR gel in the treatment of nausea and vomiting in the hospice patient |